Andrew Nava's  Instablog

Andrew Nava
Send Message
Andrew Nava LLC is a healthcare focused consulting and investment firm. Prior to launching Andrew Nava LLC, I was a venture analyst, buy-side analyst, and most recently, the Director of Research at Actin Biomed, a New York-based healthcare investment firm where I was responsible for the medical,... More
My company:
Andrew Nava, LLC
  • Biotech Regulatory Events (Non-PDUFA) - Snapshot from 0 comments
    Apr 19, 2010 7:36 AM | about stocks: PRSN, SRPT, MSTX

    Below is a short list of regulatory-related events (non-PDUFA) from, a biotechnolgy and pharmaceutical database covering more than 290 publicly-traded companies and over 1000 profiles of approved and development-stage drugs, devices and diagnostics.

    Regulatory Catalysts (non-PDUFA)

    Adventrx Pharmaceuticals (ANX)

    ANX is expected to discuss its refuse-to-file letter for its ANX-530 (vinorelbine emulsion) NDA with the FDA. On March 31, ANX received a refuse to file letter stating that the data included in the December 2009 NDA submission from the intended commercial manufacturing site was insufficient to support a commercially-viable expiration dating period.  No clinical or nonclinical issues were identified.  Timing: Last week of April

    BSD Medical Corporation (BSDM)

    On March 22, 2010, BSDM filed its 510K for the MTX-180, the company's MicroThermX Microwave System for soft tissue ablation.  The FDA typically has 90 days to respond.  Of note, BSDM's BSD-2000 has a pending HDE marketing approval for for cervical carcinoma.  The FDA has asked for questions relating to the device back in November 2009, but no updates have been provided since then.
    Timing: 2Q10 (MTX-180), BSD-2000 (unknown)

    AVI BioPharma (AVII)

    AVII stated in its recent 10-K that it has completed the necessary preclinical GLP work for AVI-4658 and expects to submit its response to the FDA in 1H10 (now 2Q10).  The FDA put a full clinical hold on the AVI-4658 IND in 2009 requesting a set of Good Laboratory Practice (NYSE:GLP) compliant preclinical studies. A Phase 1/2 UK study in Duchenne muscular dystrophy patients is currently ongoing.  No U.S. patients have yet been treated with AVI-4658.
    Timing: Submit data to FDA in 2Q10

    For more regulatory events or to learn more about the companies and programs above, please visit

    Disclosure: No Positions

    Stocks: PRSN, SRPT, MSTX
Back To Andrew Nava's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.